A Preliminary Study of Serum Apelin Levels in Patients with Head and Neck Cancer

Aktan M., Ozmen H.

EURASIAN JOURNAL OF MEDICINE, cilt.51, sa.1, ss.57-59, 2019 (ESCI) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 51 Sayı: 1
  • Basım Tarihi: 2019
  • Doi Numarası: 10.5152/eurasianjmed.2018.18411
  • Dergi Adı: EURASIAN JOURNAL OF MEDICINE
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.57-59
  • Anahtar Kelimeler: Apelin, radiotherapy, head and neck cancer, EXPRESSION, RECEPTOR
  • Atatürk Üniversitesi Adresli: Evet

Özet

Objective: Treatment planning is primarily based on the tumor node metastasis (TNM) staging system for head and neck cancer (HNC). However, TNM does not give sufficient information about biological aggressiveness, treatment response, and prognosis. New molecular markers are needed for individualized cancer treatment. Apelin is a bioactive peptide and an endogenous ligand for the G protein-coupled receptor (APJ). Its expression is induced under hypoxic conditions. Apelin and its receptor APJ are important factors in physiological angiogenesis and may be novel targets for anti-angiogenic tumor therapies. This preliminary study aimed to investigate whether there was a difference in serum apelin levels between patients with HNC and control group and also to compare the serum apelin levels before and after radiotherapy.